


The AMR Benchmark: Industry activity to mitigate environmental AMR

Damiano de Felice, Director of Strategy, Access to
Medicine Foundation

World Water Week, Stockholm, 28 August

The Antimicrobial Resistance Benchmark

- A biennial report that assesses and compares what different pharmaceutical companies are doing to limit drug-resistant infections
- Fully independent from pharmaceutical companies
- Funded by the UK and Dutch governments
- Two-year cycle (first publication in 2018, update of methodology in 2019, second iteration in 2020)



Launch of 1st AMR Benchmark at WEF Davos 2018

access to
medicine
FOUNDATION

REUTERS World Business Markets Politics TV
Future Of Money The Trump Effect Politics North Korea

THE LANCET

Search Online First Current Issue All Issues Special Issues Multimedia Information for Authors
Technology All Content Search Advanced Search

< Previous Article Volume 390, No. 10110, p2334-2335, 25 November 2017 Next Article >

Comment
Can the Antimicrobial Resistance Benchmark blaze a new trail?
Jayasree K Iyer, Marc Mendelson
Published: 13 October 2017

STAT
Newsletters Log In / Subscribe

PHARMALOT STAT+
Pharma is urged to do more to thwart the superbug crisis

Drug companies told to do more to tackle 'superbug' crisis

The New York Times

HEALTH

GLOBAL HEALTH

New Index Rates Drug Companies in Fight Against 'Superbugs'



thebmj

News

Drug companies are starting to tackle antimicrobial resistance but could do more, report shows

BMJ 2018 ;360 doi: <https://doi.org/10.1136/bmj.k269>

(Published 23 January 2018)

Cite this as: BMJ 2018;360:k269

Support The Guardian Subscribe Find a job
The Guardian
News Opinion Sport Culture Lifestyle
UK ► UK politics Education Media Society Law Scotland Wales More

Antibiotics Number of new antibiotics has fallen sharply since 2000

Report says drugmakers need to do much more to tackle rise of superbugs

FINANCIAL TIMES myFT
Medical science + Add to myFT
GSK leads drugmakers' fight against superbugs
Report says generics manufacturers trailing in battle against antibiotic resistance
Science
Log in | My account | Contact us
Become a member Renew my subscription | Sign up for newsletters

In 2016, the pharmaceutical industry pledged to help curb the global antimicrobial resistance crisis. Michael Mortensen/Flickr (CC)
This new index ranks companies' efforts in the fight against antimicrobial resistance

PharmExec.com
Magazine Topics Events Resources Subscribe Advertise Contact Us
Europe From the Editor Global New & Noteworthy R&D Sales & Marketing Strategy
Most Read Current Issue Top Features New & Noteworthy Washington Report Webcasts
Pharma Companies' Efforts to Address Drug-Resistant Infections
Jan 23, 2018 By Pharmaceutical Executive Editors
Pharmaceutical Executive
An independent analysis of pharmaceutical industry efforts to tackle drug resistance finds that, as well as developing new drugs, companies are also dismantling the incentives that encourage sales staff to oversell antibiotics, setting limits on the concentration of antibiotics in factory wastewater released into the environment, and tracking the spread of superbugs.

The full report: www.amrbenchmark.org

access to
medicine
FOUNDATION



4

KEY FINDINGS

3

CASE STUDIES

1


PORTFOLIO ANALYSIS

1

PIPELINE ANALYSIS

30

COMPANY REPORT CARDS




30 companies across three sub-sectors

Large research-based pharmaceutical companies

GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Roche Holding AG
Sanofi
Shionogi & Co., Ltd.

Generic medicine manufacturers

Aspen Pharmacare Holdings Limited
Aurobindo Pharma Ltd.
Cipla Inc.
Dr. Reddy's Laboratories Ltd.
Fresenius Kabi AG
Lupin Limited
Macleods Pharmaceuticals Ltd.
Mylan NV
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.




Biopharmaceutical companies with priority R&D projects

Achaogen Inc.
Cempra Inc.
Entasis Therapeutics Inc.
Melinta Therapeutics Inc.
MGB Biopharma
Motif Bio plc
Nabriva Therapeutics plc
Polyphor Ltd.
Summit Therapeutics
Tetraphase Pharmaceuticals Inc.
The Medicines Company
Wockhardt Ltd.

16 metrics covering three research areas

ANTIMICROBIAL RESISTANCE BENCHMARK 2018 - METRICS



1) Breadth and depth of environmental risk management

		Breadth			Third party manufacturing sites of API and Drug Products			External waste treatment plants		
		Depth			Strategy	Audits	Limits	Strategy	Audits	Limits
		Strategy	Audits	Limits						
Large research-based pharmaceutical companies	GSK	●	●	●	●	●	●	●	●	
	Johnson & Johnson	●	●	●	●	●	●			
	Merck & Co., Inc.	●	●		●	●				
	Novartis	●	●	●	●	●		●	●	
	Pfizer	●	●	●	●	●	●			
	Roche	●	●	●	●	●	●			
	Sanofi	●	●	●	●	●		●	●	
	Shionogi	●	●	●						
Generic medicine manufacturers	Aspen	●	●							
	Aurobindo	●	●					●	●	
	Cipla									
	Dr. Reddy's	●								
	Fresenius Kabi	●	●							
	Lupin									
	Macleods	●	●							
	Mylan	●	●							
	Sun Pharma									
	Teva	●	●	●	●					

		Breadth			Third party manufacturing sites of API and Drug Products			External waste treatment plants		
		Depth			Strategy	Audits	Limits	Strategy	Audits	Limits
Large research-based pharmaceutical companies	GSK	●	●	●	●	●	●	●	●	●
	Johnson & Johnson	●	●	●	●	●	●			
	Merck & Co., Inc.	●	●		●	●				
	Novartis	●	●	●	●	●		●		●
	Pfizer	●	●	●	●	●	●			
	Roche	●	●	●	●	●	●	●		
	Sanofi	●	●	●	●	●		●	●	
	Shionogi	●	●	●						
	Aspen	●	●							
Generic medicine manufacturers	Aurobindo	●	●					●	●	
	Cipla									
	Dr. Reddy's	●								
	Fresenius Kabi	●	●							
	Lupin									
	Macleods	●	●							
	Mylan	●	●							
	Sun Pharma									
	Teva	●	●	●	●					

2) Disclosure on environmental risk management

- Out of 18 companies assessed in this area, 15 have an environmental risk-management strategy. Of these, 12 disclose their strategies publicly.
- Only one company – The Medicines Company – discloses the identities of third-party manufacturers, making it an example of best practice in this area.
- Eight companies in scope for this research area report that they have set limits for antibiotic discharge. As yet, no company discloses publicly its limits and/or levels of antibiotic discharge.

The AMR Benchmark guides and incentivises companies by...

- ...triggering positive competition
- ...building consensus and clarifying responsibilities
- ...enabling accountability
- ...empowering internal decision-makers
- ...diffusing good practices
- ...unleashing pressure from institutional investors
- ...supporting private sector participation in other global health initiatives

Next steps

- Methodology update: April-December 2018
- Next Benchmark publication: beginning of 2020
- From publishing a benchmark report to triggering industry change: green procurement of antibiotics?

Damiano de Felice

ddefelice@accesstomedicinefoundation.org

[@damidefelice](#) [@atmindex](#)